Diabetes mellitus: Pathogenesis and treatment strategies

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4113-4117

  Skyler, Jay S ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; NEUTRAL INSULIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG;

DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFECT; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PATIENT CARE; SHORT SURVEY; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIFE STYLE;

EID: 3843116771     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0306273     Document Type: Short Survey

References (40)

1. Zimmet, P. Z.; Alberti, K. G. M. M.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414, 782-787.
2. Mokdad, A. H.; Ford, E. S.; Bowman, B. A.; Dietz, W. H.; Vinicor, F.; Vales, B. S.; Marks, J. S. Prevalence of obesity, diabetes, and obesity-related health factors 2001. J. Am. Med. Assoc. 2003, 289, 76-79.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-Up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care 2003, 26, 3160-3167.
4. Gerstein, H. C.; Yusuf, S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996, 347, 949-950.
5. Ford, E. S.; Giles, W. H.; Dietz, W. H. Prevalence of the metabolic syndrome among U.S. adults. J. Am. Med. Assoc. 2002, 287, 356-359.
6. Diamond, J. The double puzzle of diabetes. Nature 2003, 423, 599-602.
7. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003, 26, 917-932.
8. Skyler, J. S.; Oddo, C. Diabetes trends in the United States of America. Diabetes/Metab. Res. Rev. 2002, 18 (Suppl. 3), S21-S26.
9. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. http://www.cdc.gov/diabetes/pubs/estimates.htm.
10. American Diabetes Association. Facts and Figures. https://www.diabetes. org/info/facts/facts_nephropathy.jsp.
11. American Diabetes Association. Facts and Figures. https://www.diabetes. org/info/facts/facts_CVD.jsp.
12. Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 683-689.
13. U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837-853.
14. Stratton, I. M.; Adler, A. I.; Neil, H. A.; Matthews, D. R.; Manley, S. E.; Cull, C. A.; Hadden, D.; Turner, R. C.; Holman, R. R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321, 405-412.
15. U.K. Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317, 703-713.
16. Hansson, L.; Zanchetti, A.; Carruthers, S. G.; Dahlöf, B.; Elmfeldt, D.; Julius, S.; Ménard, J.; Rahn, K. H.; Wedel, H.; Westerling, S. HOT study group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998, 351, 1755-1762.
17. Tuomilehto, J.; Rastenyte, D.; Birkenhager, W. H.; Thijs, L.; Antikainen, R.; Bulpitt, C. J.; Fletcher, A. E.; Forette, F.; Goldhaber, A.; Palatini, P.; Sarti, C.; Fagard, R.; Staessen, J. A. For the Systolic Hypertension in Europe Trial Investigators Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension. N. Engl. J. Med. 1999, 340, 677-684.
18. Pyrälä, K.; Pedersen, T. R.; Kjekshus, J.; Faergeman, O.; Olsson, A. G.; Thorgeirsson, G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 1997, 20, 614-620.
19. Goldberg, R. B.; Mellies, M. J.; Sacks, F. M.; Moyé, L. A.; Howard, B. V.; Howard, W. J.; Davis, B. R.; Cole, T. G.; Pfeffer, M. A.; Braunwald, E. The Care Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998, 23, 2513-2519.
20. Collins, R.; Armitage, J.; Parish, S.; Sleigh, P.; Peto, R. Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361, 2005-2016.
21. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 14. J. Am. Med. Assoc. 1992, 268, 1292-1300.
22. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324, 71-86.
23. Sacco, M.; Pellegrini, F.; Roncaglioni, M. C.; Avanzini, F.; Tognoni, G.; Nicolucci, A. The PPP collaborative group: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the primary prevention project (PPP) trial. Diabetes Care 2003, 26, 3264-3272.
24. Gerich, J. E. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin. Proc. 2003, 78, 447-456.
25. Kahn, S. E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46, 3-19.
26. Atkinson, M. A.; Eisenbarth, G. S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358, 221-229.
27. Butler, A.; Janson, J.; Bonner-Weir, S.; Ritzel, R.; Rizza, R. A.; Butler, P. C. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52, 102-110.
28. DeFronzo, R. A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 1999, 131, 281-303.
29. Nathan, D. M. Initial management of glycemia in type 2 diabetes mellitus. N. Engl. J. Med. 2002, 347, 1343-1349.
30. Inzucchi, S. E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J. Am. Med. Assoc. 2002, 287, 360-372.
31. DeWitt, D. E.; Hirsch, I. B. Outpatient insulin therapy in type I and type 2 diabetes mellitus: scientific review. J. Am. Med. Assoc. 2003, 289, 2254-2264.
32. DeWitt, D. E.; Dugdale, D. C. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. J. Am. Med. Assoc. 2003, 289, 2265-2269.
33. Kazlauskaite, R.; Fogelfeld, L. Insulin therapy in type 2 diabetes. Dis.-Mon. 2003, 49, 377-424.
34. Lebovitz, H. E. Insulin secretagogues: old and new. Diabetes Rev. 1999, 7, 139-153.
35. Cusi, K.; DeFronzo, R. A. Metformin: a review of its metabolic effects. Diabetes Rev. 1998, 6, 89-131.
36. Kirpichnikov, D.; McFarlane, S. I.; Sowers, J. R. Metformin: an update. Ann. Intern. Med. 2002, 137, 25-33.
37. Diamant, M.; Heine, R. J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003, 63, 1373-1405.
38. Lebovitz, H. E. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. 1998, 6, 132-145.
39. Whitehouse, F.; Kruger, D. F.; Fineman, M.; Shen, L.; Ruggles, J. A.; Maggs, D. G.; Weyer, C.; Kolterman, O. G. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002, 25, 724-730.
40. Hollander, P. A.; Levy, P.; Fineman, M.; Maggs, D.; Shen, L.; Strobel, S.; Weyer, C.; Kolterman, O. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: A one year randomized controlled trial. Diabetes Care 2003, 26, 784-790.